BridgeBio Pharma, Inc. (BBIO) News

BridgeBio Pharma, Inc. (BBIO): $6.80

0.17 (+2.56%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter BBIO News Items

BBIO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

BBIO News Highlights

  • For BBIO, its 30 day story count is now at 13.
  • Over the past 28 days, the trend for BBIO's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • GENE, CAH and BEAT are the most mentioned tickers in articles about BBIO.

Latest BBIO News From Around the Web

Below are the latest news stories about BridgeBio Pharma Inc that investors may wish to consider to help them evaluate BBIO as an investment opportunity.

BridgeBio Pharma GAAP EPS of -$1.01 misses by $0.16, revenue of $12.89M misses by $8.69M

BridgeBio Pharma press release (BBIO): Q4 GAAP EPS of -$1.01 misses by $0.16.Revenue of $12.89M (+10641.7% Y/Y) misses by $8.69M.Shares -4.5% PM.

Seeking Alpha | February 24, 2022

BridgeBio Pharma (BBIO) Reports Q4 Loss, Misses Revenue Estimates

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -21.69% and 61.18%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 24, 2022

BridgeBio Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Business Update

–Secured up to $750 million in non-dilutive debt financing in November 2021, extending BridgeBio’s financial runway into 2024 –Dosed first patient in Phase 1/2 trial of investigational gene therapy for congenital adrenal hyperplasia (CAH); initial data readout anticipated in second half of 2022 –Launched clinical collaboration with Amgen to study BBP-398, a potentially best-in-class SHP2 inhibitor, in combination with LUMAKRAS® (sotorasib) in advanced solid tumors with the KRAS G12C mutation –Es

Yahoo | February 24, 2022

Will BridgeBio Pharma (BBIO) Report Negative Q4 Earnings? What You Should Know

BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | February 17, 2022

BridgeBio (BBIO) to Report Q4 Earnings: What's in the Cards?

On BridgeBio Pharma's (BBIO) Q4 earnings call, investor focus is likely to be on updates on the progress of the company's pipeline candidates.

Yahoo | February 17, 2022

BridgeBio Pharma (BBIO) Dips More Than Broader Markets: What You Should Know

BridgeBio Pharma (BBIO) closed the most recent trading day at $8.54, moving -1.61% from the previous trading session.

Yahoo | February 14, 2022

BridgeBio Pharma (BBIO) Gets a Buy Rating from Mizuho Securities

Mizuho Securities analyst Salim Syed maintained a Buy rating on BridgeBio Pharma (BBIO – Research Report) today and set a price target of $25.00. The company's shares closed last Wednesday at $10.23, close to its 52-week low of $8.46. According to TipRanks.com, Syed is ranked 0 out of 5 stars with an average return of -12.9% and a 37.6% success rate. Syed covers the Healthcare sector, focusing on stocks such as Atara Biotherapeutics, Assembly Biosciences, and Coherus Biosciences. Currently, the analyst consensus on BridgeBio Pharma is a Strong Buy with an average price target of $27.20, which is a 176.7% upside from current levels.

Christine Brown on TipRanks | February 9, 2022

BridgeBio Pharma (BBIO) Outpaces Stock Market Gains: What You Should Know

BridgeBio Pharma (BBIO) closed the most recent trading day at $9.99, moving +1.83% from the previous trading session.

Yahoo | February 4, 2022

BridgeBio Pharma (BBIO) Gains But Lags Market: What You Should Know

BridgeBio Pharma (BBIO) closed the most recent trading day at $9.04, moving +1.01% from the previous trading session.

Yahoo | January 28, 2022

BridgeBio (BBIO) Begins Dosing with Gene Therapy in CAH Study

BridgeBio (BBIO) doses the first patient in a phase I/II study evaluating its investigational gene therapy candidate, BBP-631, for treating classic congenital adrenal hyperplasia.

Yahoo | January 28, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.486 seconds.